Pikkelysömör: vizsgálatok itt: Lengyelország

In Lengyelország 16 Also abroad 274

16 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.

4. fázisTaking people
An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment
Where
Bydgoszcz, Cracow, Lublin, Torun, Warsaw
People
339 worldwide
Run by
Novartis Pharma AG
See details and how to joinNCT04638647 · EU 2023-504417-67-00
2. fázisTaking people
Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
Where
Bialystok, Bydgoszcz, Elblag, Pruszków, Warsaw
Életkor
18 év and over
People
300 worldwide
Run by
AbbVie
See details and how to joinNCT06865105
1. fázisTaking people
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Where
Bialystok, Bydgoszcz, Bytom, Elblag, Krakow, Lodz, Lublin, Nowa Sól, Olsztyn, Płońsk, Poznan, Torun, Warsaw, Wroclaw
Életkor
18 év and over
People
392 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT07290036
3. fázisTaking people
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Where
Rzeszów, Sosnowiec, Warsaw
Életkor
3 év to 64 év
People
196 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00
3. fázisTaking people
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Where
Bialystok, Cracow, Elblag, Gdansk, Gdynia, Katowice, Kielce, Lodz, Lublin, Mikolow, Olsztyn, Ostrowiec Świętokrzyski, Poznan, Rzeszów, Skierniewice, Torun, Warsaw, Warszawa, Wroclaw, ZDROWIE OSTEO-MEDIC S.C. L. i A. Racewicz, A. i J. Supronik
Életkor
40 év and over
People
3040 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07116967 · EU 2023-503766-24-00
3. fázisTaking people
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Where
Bialystok, Garwolin, Lodz, Lublin, Olsztyn, Warsaw
Életkor
12 év to 17 év
People
366 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06979453 · EU 2023-506296-97-00
3. fázisTaking people
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
Where
Kraków, Lodz, Warsaw, Wroclaw
Életkor
4 év to 18 év
People
153 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT04772079 · EU 2022-502519-13-00
3. fázisTaking people
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Where
Bialystok, Białystok, Bytom, Cracow, Dąbrówka, Elblag, Katowice, Lodz, Nowa Sol, Olsztyn, Opole, Poznan, Sochaczew, Torun, Warsaw, Wroclaw
Életkor
18 év and over
People
1088 worldwide
Run by
Takeda
See details and how to joinNCT06671483 · EU 2024-513111-27-00
3. fázisTaking people
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
Where
Gdansk, Lodz, Lublin, Rzeszów, Wroclaw
Életkor
4 év to 17 év
People
110 worldwide
Run by
Takeda
See details and how to joinNCT07250802 · EU 2025-522567-15-00
3. fázisTaking people
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Where
Białystok, Bydgoszcz, Bytom, Cracow, Częstochowa, Dąbrówka, Elblag, Gdynia, Katowice, Lodz, Lublin, Nowa Sol, Olsztyn, Opole, Poznan, Sochaczew, Torun, Warsaw, Wroclaw, Wrocław
Életkor
18 év and over
People
1182 worldwide
Run by
Takeda
See details and how to joinNCT07286058 · EU 2025-522586-30-00
3. fázisTaking people
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Where
Cracow, Lodz, Lublin, Sosnowiec, Warsaw
Életkor
5 év to 17 év
People
40 worldwide
Run by
AbbVie
See details and how to joinNCT06100744 · EU 2023-506026-36-00
3. fázisTaking people
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Where
Bialystok, Cracow, Elblag, Krakow, Lodz, Osielsko (Bydgoszcz), Poznan, Warsaw, Wroclaw
Életkor
18 év and over
People
320 worldwide
Run by
Janssen - Cilag International
See details and how to join2023-505121-14-00 · EU 2023-505121-14-00
2/3. fázisTaking people
Study of the efficacy and safety of etanercept treatment in patients with SAPHO syndrome
Where
Olsztyn, Szczecin, Warsaw
Életkor
18 év and over
People
60
Run by
Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicher
See details and how to join2024-516919-25-00 · EU 2024-516919-25-00
4. fázisTaking people
A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
Where
Bydgoszcz, Bytom, Elblag, Krakow, Kraków, Lublin, Poznan, Warsaw, Warszawa, Wroclaw
Életkor
18 év and over
People
100 worldwide
Run by
CARE ARTHRITIS LTD.
See details and how to joinNCT06454188 · EU 2023-510242-24-00
No phaseTaking people
An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
Where
Poznan, Wroclaw
Életkor
18 év to 75 év
People
1200 worldwide
Run by
AbbVie
See details and how to joinNCT06764693
3. fázisNot yet taking people in Lengyelország
A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy
Where
Bytom, Gdansk, Lodz, Lublin, Piaseczno, Pruszkow, Wroclaw
Életkor
18 év and over
People
705 worldwide
Run by
Can-Fite BioPharma
See details and how to joinNCT06643260 · EU 2024-519919-34-00